NASDAQ$NRIX
Nurix Therapeutics Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Nurix reported fourth quarter and fiscal year 2020 financial results and provided a corporate update.
Nurix Therapeutics reported collaboration revenue of $6.7 million for the fourth quarter of 2020, with a net loss of $19.9 million, or $0.51 per share. The company's cash, cash equivalents, and investments totaled $372.0 million as of November 30, 2020.
- First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies
- Three additional wholly owned programs expected to enter clinical trials in 2021
- Expanded Sanofi collaboration resulting in option exercise payment of $22 million
- Year-end cash and investments totaling $372 million
Headline financials
Revenue & EPS history
Nurix · Revenue · Quarterly
$6.69M
Revenue by segment
Nurix · $6.7M total across 1 segment · Q4 2020
- Collaboration revenue$6.7M—100.0%
Forward guidance
Nurix anticipates commencing Phase 1 trials for NX-1607, NX-5948 and DeTIL-0255 in the second half of 2021 and dosing the first patient in a Phase 1a/1b trial for NX-2127 in the first quarter of 2021.
Tailwinds
- Open IND and anticipates dosing the first patient in a Phase 1a/1b trial for NX-2127 in the first quarter of 2021.
- Anticipates commencing a Phase 1 trial for NX-1607 in the second half of 2021.
- Anticipates commencing a Phase 1 trial for NX-5948 in the second half of 2021.
- Anticipates commencing a Phase 1 trial for DeTIL-0255 in the second half of 2021
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
+2.9%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.8%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+35.6%
Q1 2023
Best reaction
-13.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -4.2% | +4.5% | +5.9% | |
| Q4 2025 | -1.7% | -6.0% | -10.6% | |
| Q3 2025 | -10.1% | -4.7% | +13.4% | |
| Q2 2025 | -4.3% | -11.7% | -16.8% | |
| Q1 2025 | +7.8% | +12.0% | +4.8% | |
| Q4 2024 | +0.5% | -3.1% | -21.0% | |
| Q3 2024 | +15.1% | +18.1% | +25.1% | |
| Q2 2024 | +17.7% | +12.7% | +2.9% | |
| Q1 2024 | -1.5% | -11.6% | -22.7% | |
| Q4 2023 | +7.2% | +9.6% | +42.0% | |
| Q3 2023 | -3.9% | -8.3% | -20.5% | |
| Q2 2023 | -2.2% | -2.3% | -7.3% | |
| Q1 2023 | +35.6% | +29.9% | +14.8% | |
| Q4 2022 | +1.0% | -6.2% | -25.8% | |
| Q3 2022 | -13.2% | -12.6% | +2.5% | |
| Q2 2022 | +22.7% | +10.7% | +34.3% | |
| Q1 2022 | +7.2% | -3.7% | -30.8% | |
| Q4 2021 | -4.6% | +2.3% | -14.1% | |
| Q3 2021 | +0.1% | -1.6% | +18.3% | |
| Q2 2021 | -5.1% | +8.6% | +32.2% | |
| Q2 2020 | -5.1% | +8.6% | +32.2% | |
| Q1 2021 | +12.6% | +9.0% | -5.4% | |
| Q4 2020 | +3.0% | -4.2% | -1.3% | |
| Q3 2020 | -4.7% | +3.8% | +14.4% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro